Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2012

01-12-2012 | Editorial

Depicting the evolving scenario of translational-guided drug development

Authors: G. Argilés, J. Rodon, J. Tabernero

Published in: Clinical and Translational Oncology | Issue 12/2012

Login to get access

Excerpt

The development process of most important targeted agents currently used in oncologic clinical practice has unveiled the fact that using these types of drugs efficaciously is best supported by the availability of appropriate predictive biomarkers. Conversely, the magnitude of the effect obtained from administering such drugs to patients that respond to them on the basis of known biomarkers is likely to be diluted by concomitantly administering the drugs to an unselected patient population as well. This scenario could compromise the future of bona fide compounds due to the bias of non-selection when measuring drug benefit. …
Literature
1.
Cunningham D, Humblet Y et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345PubMedCrossRef
2.
Allegra CJ, Jessup JM et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27(12):2091–2096PubMedCrossRef
3.
Argiles G, Dienstmann R et al (2012) Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol 8(4):373–389PubMedCrossRef
4.
Broadbridge V, Karapetis C, Price T (2012) Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther 12(5):555–565PubMedCrossRef
5.
Rodon J, Saura C et al (2012) Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 9(6):359–366PubMedCrossRef
6.
Kwak E, Bang Y et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703PubMedCrossRef
7.
Chapman P, Hauschild A et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516PubMedCrossRef
8.
García V, Cassier P, de Bono J (2011) Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress. Cancer Discov 1(3):207–212PubMedCrossRef
Metadata
Title
Depicting the evolving scenario of translational-guided drug development
Authors
G. Argilés
J. Rodon
J. Tabernero
Publication date
01-12-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0969-x

Other articles of this Issue 12/2012

Clinical and Translational Oncology 12/2012 Go to the issue

Research Article

Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model

Research Article

Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer

Educational Series – Red Series*

Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy

Educational Series – Blue Series

Therapeutic nanosystems for oncology nanomedicine

Research Article

Is obesity always a risk factor for all breast cancer patients? c-erbB2 expression is significantly lower in obese patients with early stage breast cancer

Review Article

Conservative surgery, external radiotherapy, and HDR brachytherapy in a single fraction of 7 Gy in early breast cancer: long-term toxicity and esthetic assessment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits